Form 4: Foghorn Therapeutics Director Adam Koppel Resigns from Board

Adam Koppel has resigned from the Board of Directors of Foghorn Therapeutics, effective December 29, 2024.

Summary

• Adam Koppel, a director at Foghorn Therapeutics Inc., has resigned from the company's Board of Directors.
• The resignation was effective as of December 29, 2024.
• This Form 4 filing serves as a voluntary exit report, indicating that Mr. Koppel will no longer be required to file further reports related to his position at Foghorn Therapeutics.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a director's resignation, which is a routine corporate event. There is no indication of positive or negative sentiment.

Industry Context

Director resignations are a normal part of corporate governance, and this filing is a routine disclosure.

Comparison to Industry Standards

• Director resignations are common across the biotechnology industry, and this event is not unusual.
• Companies regularly update their board composition to align with strategic goals and governance requirements.

Management Changes

Stakeholder Impact

• The resignation of a director may have a minor impact on shareholder confidence, but is generally considered a normal corporate event.

Key Dates

Keywords

Foghorn Therapeutics, Board of Directors, Resignation, Director, Form 4, Corporate Governance